Medical News

RSS

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.

12 Aug 2010

PDL BioPharma retires $61.7 million of 2.75% Convertible Subordinated Notes due 2023

PDL BioPharma, Inc. announced today that it has completed the retirement of $61.7 million in aggregate principal amount of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 for consideration consisting of the issuance of 11.1 million shares of the Company's common stock.

12 Aug 2010

Survey finds high level of noncompliance with PPE protocols among safety professionals

Nearly all of the safety professionals in a survey released today said that workers in their organizations had at some point failed to wear the necessary safety equipment while on the job. An exceedingly high 98 percent of respondents who attended the recent American Society of Safety Engineers (ASSE) show in Baltimore answered "yes" when asked if they had observed workers not wearing safety equipment when they should have been, according to the survey, which was conducted by Kimberly-Clark Professional.

12 Aug 2010

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Genta Incorporated today announced financial results for the quarter ending June 30, 2010.

12 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

12 Aug 2010

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.

12 Aug 2010

Gentium second-quarter total revenues increase to EUR 7.55 million

Gentium S.p.A. today reported financial results for the first half of 2010 and for the quarter ended June 30, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial statements are prepared using the Euro as its functional currency.

12 Aug 2010

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Perrigo Company today announced results for its fourth quarter and full year ended June 26, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.

12 Aug 2010

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.

12 Aug 2010

Aradigm reports net loss of $4.1M for second-quarter 2010

Aradigm Corporation today announced financial results for the second quarter and six months ended June 30, 2010.

12 Aug 2010

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm Inc. today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated.

12 Aug 2010

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

NextWave Pharmaceuticals and Tris Pharma, both privately held companies, announced a new collaboration agreement to enhance NextWave's CNS product portfolio utilizing Tris Pharma's unique drug delivery technology for liquid and solid formulations. Tris has reacquired the rights to non CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

12 Aug 2010

Centric Health second-quarter net income increases 154% to $1.3 million

Centric Health Corporation, a diversified healthcare company with a vision to become Canada's premier healthcare company providing innovative solutions centered around patients and healthcare professionals, today announced strong financial results for the second quarter ended June 30, 2010.

12 Aug 2010

Accretive Health second-quarter net services revenues increase 21% to $151.9 million

Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services, today announced financial results for the quarter ended June 30, 2010.

12 Aug 2010

First Edition: August 12, 2010

Some of today's headlines highlight how the new health reform law is playing beyond Washington, D.C.'s beltway.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Medical News

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

PDL BioPharma retires $61.7 million of 2.75% Convertible Subordinated Notes due 2023

Survey finds high level of noncompliance with PPE protocols among safety professionals

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Gentium second-quarter total revenues increase to EUR 7.55 million

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Pharmasset receives fast track designation from FDA for PSI-7977

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

Aradigm reports net loss of $4.1M for second-quarter 2010

Labopharm second-quarter total revenue increases to $6.8 million

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

Centric Health second-quarter net income increases 154% to $1.3 million

Accretive Health second-quarter net services revenues increase 21% to $151.9 million

First Edition: August 12, 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News